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Available online 4 September 2017A central pathogenic event of Alzheimer's disease (AD) is the accumulation of the Aβ42 peptide, which is gener-
ated from amyloid-β precursor protein (APP) via cleavages by β- and γ-secretase. We have developed a class of
soluble 2-aminothiazole γ-secretase modulators (SGSMs) that preferentially decreases Aβ42 levels. However,
the effects of SGSMs in AD animals and cells expressing familial AD mutations, as well as the mechanism of γ-
secretasemodulation remain largely unknown. Here, a representative of this SGSMscaffold, SGSM-36, was inves-
tigated using animals and cells expressing FADmutations. SGSM-36 preferentially reduced Aβ42 levels without
affecting either α- and β-secretase processing of APP nor Notch processing. Furthermore, an allosteric site was
identifiedwithin the γ-secretase complex that allowed access of SGSM-36 using cell-based, fluorescence lifetime
imaging microscopy analysis. Collectively, these studies provide mechanistic insights regarding SGSMs of this
class and reinforce their therapeutic potential in AD.g Res
Dep
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Notch1. Introduction
Alzheimer's disease (AD) is a devastating neurodegenerative disor-
der and the leading cause of dementia. There is currently no treatment
available to slow or halt disease progression. The underlying mecha-
nisms of AD on the cell andmolecular levels are still not completely elu-
cidated. Considerable genetic, pathological, biochemical, and molecular
biological evidence supports the amyloid-cascade hypothesis, stating
that the production and excessive accumulation of a small peptide, am-
yloid-β (Aβ), is the primary pathological event leading to AD (Gandy,
2005; Hardy and Selkoe, 2002; Tanzi and Bertram, 2005). Specifically,
the accumulation of Aβ, particularly the neurotoxic Aβ42 peptide,earch Unit, MassGeneral
artment of Neurology,
estown, MA, 02129-2060,
helix.mgh.harvard.edu
is an open access article underaffects neuronal synaptic functions and triggers an inflammatory re-
sponse which is followed by neuritic injury and the generation of path-
ological tau proteins, ultimately leading to neuronal dysfunction and
cell death.
AD is a genetically complex disease. Four AD genes (APP, PSEN1,
PSEN2 and APOE) have been identifiedwhich primarily serve to increase
the ratio of Aβ42 to Aβ40 or in the case of the Swedish mutation, abso-
lute Aβ peptide levels. The imbalance triggered by these genetic aberra-
tions enhances the oligomerization of Aβ into neurotoxic assemblies
and ultimately leads to dementia (Bertram and Tanzi, 2008; Choi et
al., 2014; Tanzi and Bertram, 2005). In the amyloidogenic pathway,
Aβ is produced via sequential proteolytic cleavage of the type I trans-
membrane protein, amyloid-β (A4) precursor protein (APP) by β- and
γ-secretase, respectively (Bertram and Tanzi, 2008; Zhang and
Saunders, 2007). γ-Secretase is a heterogeneous protein complex,
formed by at least four transmembrane proteins: presenilin (PS1),
presenilin enhancer 2 (PEN2), nicastrin, and anterior pharynx-defective
1(APH-1) (Bertram and Tanzi, 2008; Edbauer et al., 2003; Sisodia and St
George-Hyslop, 2002). Over 200 mutations in the PS1-encoding gene
(PSEN1) have been identified to cause early-onset familial ADthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the disease. γ-Secretase regulates the intramembrane proteolysis
of APP and numerous other substrates that have previously under-
gone ectodomain shedding, including Notch (Gu et al., 2004; Kopan
and Ilagan, 2004; Sisodia and St George-Hyslop, 2002). The process-
ing of Notch at the ε-site (or s3) represents a critical function of γ-
secretase which yields a large cytoplasmic peptide, the Notch intra-
cellular domain (NICD), which can translocate to the nucleus and is
essential for cellular differentiation and development (Herreman et
al., 1999; Kopan et al., 1994).
One essential strategy for AD therapeutics has focused specifically on
APP processing and attenuating Aβ production (Bertram and Tanzi,
2008; Selkoe, 2001; Zhang, 2012, 2017). Initially, a class of drugs
known as γ-secretase inhibitors (GSIs), were developedwhich potently
inhibit γ-secretase activity. Despite the ability to preclude Aβ produc-
tion, GSIs exhibit unfavorable activities that result in cell toxicity
through increasing the levels of APP carboxy-terminal fragments
(CTFs; CTFα and CTFβ), and side effects potentially elicited through
down-regulation of Notch processing (Mitani et al., 2012). One of the
well-characterized GSIs is semagacestat (or LY450139) (Doody et al.,
2013;Mitani et al., 2012). Although it decreased the levels of all Aβ spe-
cies (Potter et al., 2013), semagacestat recently failed in the pivotal
phase 3 clinical trial for AD (Doody et al., 2013). Nevertheless, the re-
sults provide useful knowledge toward the features of a therapeutic
for AD, which should avoid unfavorable adverse events associated
with inhibition strategies in targeting either γ-, or β-secretease (De
Strooper, 2014; Ward et al., 2017; Willem et al., 2015). Furthermore,
this result provides evidence for a general need of improved under-
standingwith respect to the critical biological roles of γ-secretase espe-
cially within the context of therapeutic development (De Strooper,
2014; Zhang, 2017).
A group of smallmoleculewith amore promising therapeuticmech-
anism are known as γ-secretase modulators (GSMs), which modulate
the cleavage activity of γ-secretase (and likely a host of other sub-
strates) and specifically reduce the levels of the fibrillogenic Aβ42 pep-
tide without altering the ε-site cleavage of APP or numerous other γ-
secretase substrates, including Notch (Brendel et al., 2015; Imbimbo et
al., 2007; Kounnas et al., 2010; Rogers et al., 2012). Since GSMs spare
the ε-site processing of Notch, these compounds are considered likely
to be safer and better tolerated than GSIs.
Previously,we reported the development and characterization of a se-
ries of GSMs with promising biological activities (Kounnas et al., 2010).
The initial aminothiazole class of compounds displayed high potency for
inhibiting the secretion of the Aβ42 peptide, however these compounds
also suffered frompoor aqueous solubility (Kounnas et al., 2010). Utilizing
rational medicinal chemistry design, a class of aminothiazole GSMs was
developed with improved physicochemical properties which include in-
creased aqueous solubility and thus were referred to as soluble GSMs
(or SGSMs)(Wagner et al., 2014). Importantly, these SGSMs were effec-
tive at reducing the levels of Aβ using cell-based models (D'Avanzo et
al., 2015; Wagner et al., 2014). Further pharmacokinetic evaluation of
this aminothiazole class of SGSMs in mice identified a lead compound,
SGSM-36, which showed good brain penetration, as well as good clear-
ance, half-life, and volume of distribution (Rynearson et al., 2016).
These results collectively support the continued development of this
class of compounds as a potential therapy for AD (Rynearson et al., 2016).
To advance our understanding of this aminothiazole class of com-
pounds, further investigation using AD animal-basedmodels andmecha-
nistic studies were required to establish proof of concept in future clinical
applications. Thus, in this study, we further characterized the representa-
tive aminothiazole SGSM with improved physicochemical properties for
the potential effects on γ-secretase processing of APP in vivo using a
well-studied AD mouse model, in addition to cell models of the disease.
Furthermore, we investigated the effects of our representative
aminothiazole SGSM on PS1 conformation using cell-based, fluorescence
lifetime imaging microscopy (FLIM) analysis.2. Materials and Methods
2.1. Animal Studies
All procedures conducted on animals were approved byMGH IACUC
and conform to current animal welfare guidelines. The design and pro-
tocol followed our previous report (Kounnas et al., 2010). Briefly,
Tg2576 mice which express human APP695 gene harboring the Swed-
ish double mutation (KM670/671NL) were used (Hsiao et al., 1996;
Kounnas et al., 2010). 3-Month old female Tg2576 mice were sourced
from Taconic Biosciences (APPSWE; Model 1349) and used for short-
term efficacy studies (n= 7 or n= 8 per group). Daily dosing was per-
formed for three consecutive days by oral gavage in an 80% PEG 400 (v/
v) vehicle. Three hours post drug administration on the last day, the an-
imals were transcardially perfused under isoflurane anesthesia, blood
was collected from mice via cardiac puncture into heparinized tubes.
Whole blood was centrifuged (10,000 g for 10 min) to isolate plasma,
aliquoted and stored at−80 °C for analysis. After brain dissection, tissue
was processed for postmortem analyses, including biochemical studies.
2.2. Brain Extraction
Mouse brains were processed using previously reported methods
(Kounnas et al., 2010; Veeraraghavalu et al., 2013, 2014). Briefly, brain
hemispheres were homogenized in Tris-buffered saline (TBS) contain-
ing 1× Halt protease inhibitor cocktail (Thermoscientific) via polytron
and applied to the following steps. Samples from the TBS homogenates
were extracted with M-PER Mammalian Protein Extraction Reagent
with 1× Halt protease inhibitor cocktail (Thermoscientific) and spun
at 10,000 g for 20 min at 4 °C. The supernatant (MTBS) was used to de-
tect total proteins, including membrane-bound proteins. In addition,
TBS homogenates were spun at 100,000 g for 60 min at 4 °C. The super-
natant was used to detect TBS soluble Aβ levels; and the pellets of TBS
homogenates were further homogenized in 70% formic acid via
polytron and spun at 100,000 g for 60 min. Finally, the supernatant of
the formic acid extracts after centrifugation were used to detect TBS-in-
soluble Aβ levels. All samples were neutralized in 1 M Tris base buffer
and then diluted before performing ELISA or Meso Scale analysis.
2.3. Cell Culture and Mouse Primary Cortical Neuron Culture
The Chinese hamster ovary CHO cell line stably expressing Indiana
mutation in APP, also known as 7PA2 cells, has been previously reported
(Walsh et al., 2002; Welzel et al., 2014). These cells were cultured and
maintained on regular tissue culture plates in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% fetal bovine serum,
2mML-glutamine, 100 units perml penicillin, 100 μg perml streptomy-
cin, and 200 μg/ml G418. Serum-free medium was utilized for experi-
ments using 7PA2 cells. CHO cells stably expressing wild type APP751
and transiently transfected with the GFP-PS1-RFP FRET reporter has
been previously reported (Uemura et al., 2009) and were used for the
FLIM assay of PS1 conformational changes. Mouse primary neuronal
cultures were prepared from cerebral cortex of CD-1 wild type mouse
embryos at gestation day 16–18, as described previously (Berezovska
et al., 1999). Briefly, the brain tissue was dissociated with Papain Disso-
ciation Kit (Worthington Biochemical Corporation, Lakewood, NJ). The
dissociated cells were plated on poly-D-lysine coated dishes and main-
tained in Neurobasal Medium supplemented with 2% B27, 1% Glutamax
and 1% penicillin and streptomycin (ThermoScientific,Waltham,MA) in
a 5% CO2 incubator at 37 °C for 8–11 days in vitro (DIV).
The three-dimensional (3D) human neural cell culture and treat-
ment were performed using the previously published protocol (Choi
et al., 2014). Briefly, the HReN-mGAP cells expressing APP Swedish
and London mutations and PSEN1 δE9 mutation were utilized. They
were plated at a cell density of 20,000,000 cells per ml in a mixture of
Matrigel and then 3D-differentiated for five weeks. Subsequently, cells
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2 weeks, and then medium was collected and applied to Aβ MSD
analysis.2.4. Reagents and Compounds
The GSI N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-(S)-phenylglycine
t-butyl ester, also known as DAPT, was sourced from Tocris (catalog #:
2634). SGSM-36, N-(3-(tert-butyl)-1-ethyl-1H-pyrazol-5-yl)-4-(3-
fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl)thiazol-2-amine,was de-
signed at theUniversity of California, SanDiego and synthesized atAlba-
ny Molecular Research, Inc. (Albany, NY) and determined to be N95%
pure based on liquid chromatography-tandem mass spectrometry and
nuclear magnetic resonance analyses. SGSM-36 and close structural an-
alogs also containing the 2-aminothiazole C-ring, have previously been
investigated in cell culture-based studies (D'Avanzo et al., 2015). SGSM-
36 was selected from the compounds within this particular family of
aminothiazole-derived SGSMs based on good activity for attenuating
Aβ42 and favorable physicochemical properties established by vigorous
in vitro ADMET (absorption, distribution, metabolism, excretion, and
toxicity) analysis to undergo further in vitro and in vivo studies
(Rynearson et al., 2016).2.5. Antibodies
The APP C-terminal polyclonal antibody (targeting the last 19 amino
acids of APP) was purchased from Sigma (Catalog #: A8717) and the
previously reported G12A antibody (Griciuc et al., 2013; Wang et al.,
2015) were used to detect full length APP and APP-CTFs. The 6E10 anti-
body (Covance), a monoclonal antibody (mAb) reactive to amino acid
residues 1–16 of Aβ from the N-terminal sequence, detects sAPPα and
Aβ in the medium, as well as full length APP and APP-CTFβ in lysates.
The mAb 22C11 was obtained from Millipore (Catalog #: MAB348)
and active against residues 66–81 of APP from the N-terminal sequence.
The polyclonal antibody sAPPβ was purchased from IBL (Catalog #:
18,957). The mAb Notch1 was obtained from Abcam (Catalog #:
EP1238Y) and was produced by immunizing animals with a synthetic
peptide corresponding to human Notch1 residues 2500–2600. It was
used to detect the full length and cleaved Notch1 proteins. The PS1 N-
terminal (NT) antibody (APS11), raised against PS1 N-terminus and
the PS1 loop antibody (EP2000Y), raised against large cytosolic loop
domain of PS1, were obtained from Abcam (Catalog #: ab15456 and
ab76083, respectively). The PS1 C-terminal (CT) antibody, raised
against PS1 C-terminus was acquired from Sigma (Catalog #: P7854).
The mAbMyc-Tag (71D10) was purchased from Cell Signaling (Catalog
#: 2278). The β-actin antibody or GAPDH was purchased from Sigma
and used as an internal protein control. The Alexa Fluor 488 and Cy3
conjugated secondary antibodies were purchased from
ThermoScientific and Jackson ImmunoResearch, respectively. The
HRP-conjugated secondary antibodies (anti-mouse and anti-rabbit)
were purchased fromPierce and previously reported. The dilution factor
for primary and secondary antibodies was 1: 1000 and 1: 10,000,
respectively.2.6. Cell Lysis and Protein Amount Quantification
Cell conditionedmedium and lysates were prepared using previous-
ly reported methods (Ward et al., 2017; Zhang et al., 2010a, 2007).
Briefly cells were lysed in M-PER (Mammalian Protein Extraction Re-
agent, Thermoscientific) with 1× Halt protease inhibitor cocktail
(Thermoscientific). The lysates were collected, centrifuged at 10,000 g
for 20 min, pellets were discarded, and supernatants were transferred
to a new Eppendorf tube. Total protein was quantified using the BCA
protein assay kit (Pierce).2.7. Western Blotting Analysis (WB)
WB analysis was carried out by the method previously described
(Ward et al., 2017; Zhang et al., 2010a, b). Briefly, proteinswere extract-
ed and applied to electrophoresis using the Novex NuPAGE SDS-PAGE
Gel System (Thermo Fisher Scientific), followed by membrane transfer,
antibody incubation, and signal development. The house-keeping pro-
tein, β-actin or GAPDH, was used as an internal control. The VersaDoc
imaging system with Quantity One software (Bio-Rad) and the Odys-
sey® Fc with Image Studio imaging software (LI-COR) were used to de-
velop the blots and quantify the proteins of interest following protocols
previously described (Ward et al., 2017; Zhang et al., 2010a, b). ImageJ
was also used for the analyzing of blots.
2.8. AβMeasurements
Aβmeasurements were performed following the previously-report-
ed protocols and as suggested by the manufacturers, including Wako
(Zhang et al., 2010a, 2010b) and MSD MesoScale Diagnostics
(Kounnas et al., 2010). In brief, Aβ40 and Aβ42 levels were quantified
using a sandwich enzyme-linked immunosorbent assay (ELISA) from
Wako. The MSD triplex (Aβ40, Aβ38 and Aβ42) were measured via an
electrochemiluminescence-based multi-array method to validate the
results observed for the ELISA (Wako). Aβ levels from samples treated
with GSMs or GSIswere compared and normalized to those levels of ve-
hicle control treatment.
2.9. Immunocytochemistry
The methods for immunocytochemistry were previously reported
(Uemura et al., 2011; Zoltowska et al., 2017). Briefly, cells were fixed
by 15-minute incubation with 4% paraformaldehyde (PFA) in phos-
phate buffered saline (PBS) and then washed with PBS and perme-
abilized with 0.1% Triton-× 100 in PBS. The non-specific binding of the
antibodies in the samples was blocked by 1.5% normal donkey serum
(NDS) (Jackson ImmunoResearch Labs, West Grove, PA) in PBS for 1 h.
The cells were then incubated overnight at 4 °Cwith respective primary
antibodies: mouse anti-PS1 N-terminus and rabbit anti-PS1 loop or PS1
CT antibodies diluted in PBS supplemented with 1.5% NDS. This was
followed by 1-h incubation with corresponding Alexa Fluor 488- and
Cy3-conjugated secondary antibodies. Vectashield mounting medium
was used to mount the slides (Vector Laboratories, Inc., Burlingame,
CA), which was subsequently applied to PS1 conformation analysis via
FLIM.
2.10. Fluorescence Lifetime Imaging Microscopy (FLIM) Analysis
PS1 conformationwas analyzed using previously established Förster
resonance energy transfer (FRET)-based FLIM analysis (Maesako et al.,
2017; Uemura et al., 2009; Zoltowska et al., 2017), which allows deter-
mination of the proximity between PS1 subdomains, e.g. the N-termi-
nus (NT) and C-terminus (CT) or the cytoplasmic loop domain. Briefly,
the CHO cells were stained with the primary antibodies specific for var-
ious PS1 subdomains, and then Alexa Fluor 488 (AF488) and Cy3-la-
beled secondary antibodies were used as the donor and acceptor
fluorophores, respectively. AF488 fluorophore (two-photon excitation
at 780 nm wavelength) was excited using pulsing Chameleon
Ti:Sapphire laser (Coherent Inc., Santa Clara, CA). The donorfluorophore
lifetimes were recorded using a high-speed photomultiplier tube (MCP
R3809; Hamamatsu, Bridgewater, NJ) and a fast time-correlated single-
photon counting acquisition board (SPC-830; Becker & Hickl, Berlin,
Germany).When the acceptor is present close to the donor, the transfer
of the donor emission energy (FRET) to the acceptor occurs, resulting in
the shortening of the donor fluorophore lifetime (τ2). Samples, where
the anti-PS1 loop CT antibodywas omitted,were used as a negative con-
trol to determine the baseline lifetime of the donor fluorophore
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calculated using the following equation: EFRET% = (τ1 − τ2) divided
by τ1 ∗ 100%. The data were analyzed using SPC Image software (Becker
& Hickl, Berlin, Germany).
2.11. Data Analysis
β-Actin was used in theWestern blotting analysis to account for any
differences in loading. The levels of various proteins, e.g. full length APP,
C99, and C83 were normalized to the β-actin values from the same lane
or sample. All results were demonstrated as means ± S.E. from at least
three experiments. We used the two-tailed Student's t-test or one-way
analysis of variance (ANOVA), as appropriate, to reveal the differences
between the experimental groups. P values b0.05 were considered sta-
tistically significant.
3. Results
3.1. SGSM-36 Preferentially Decreases Aβ42 Levels in Tg2576 Mice
The Tg2576 mouse model is a well-characterized model for
studying AD in which mice overexpress the EOFAD-linked Swedish
mutation-containing form of APP that increases total Aβ levels
(Hsiao et al., 1996). Prior experiments have demonstrated that
acute administration of the parent 2-aminothiazole GSM effectively
reduced brain and plasma Aβ42 levels in Tg2576 mice (Kounnas et
al., 2010). Consequentially, experiments were designedwhich inves-
tigate whether acute treatment with SGSM-36 (Fig. 1A), a small mol-
ecule compound with improved physicochemical properties, would
also reduce Aβ42 levels in the brain and plasma of Tg2576 mice
(Kounnas et al., 2010). Following a previously-established protocol,Fig. 1.Aminothiazole-derived compound SGSM-36was designed based on parent compound, a
The parent aminothiazole compound, NGP-555, was optimized for improved properties, which
to an AD transgenic animal-based efficacy study for Aβ42 inhibition (B–D). Three-month old fem
36 (n = 7) for 3 consecutive days. Mouse brains were processed to generate TBS-soluble and
analysis to determine Aβ levels and Aβ (42:40) ratios. A. Structures of aminothiazole-based p
TBS-soluble Aβ40 and Aβ42 levels compared to vehicle (p N 0.05). C. SGSM-36 significan
significantly decreased plasma Aβ42 levels compared to vehicle (p b 0.05). E. SGSM-36 decre
*p b 0.05; **p b 0.01.Tg2576 mice were treated with vehicle or 25 mg/kg SGSM-36 once
daily for three consecutive days (Kounnas et al., 2010). Upon com-
pletion of the study, the brains were harvested 3 h after last dose
and then processed to generate a TBS soluble fraction and a TBS in-
soluble fraction. The TBS insoluble samples were further processed
in 70% formic acid to generate TFA sample fractions. Subsequently,
the Meso Scale Aβ triplex assay was carried out to the detect Aβ
levels (Aβ38, Aβ40 and Aβ42) in the processed samples.
Aβ40 and Aβ42were both detected within the samples; however,
Aβ38 was not detected due to the low levels of this peptide, consis-
tent with other AD transgenic models (Minter et al., 2016). Treat-
ment with SGSM-36 did not significantly change Aβ40 or Aβ42
levels compared to vehicle for the TBS-soluble fractions (Fig. 1B).
The raw values of Aβ levels were also represented (Supplementary
Fig. 1). A 30.5% decrease in Aβ42 levels in the soluble fraction was as-
sociated with acute treatment, although the difference was below
the statistical significance level using ANOVA (p N 0.05). The levels
of Aβ40 in the TBS-insoluble fractions were suppressed by 26.9%
when compared to vehicle, which did not reach the statistical signif-
icance level (p N 0.05). Importantly, SGSM-36 treatment led to a sig-
nificant decrease in Aβ42 levels (42.0% reduction) in TBS-insoluble
brain samples (p b 0.05) (Fig. 1C).
Furthermore, the effects of SGSM-36 on plasma Aβ levels were de-
termined. As in the brain soluble fraction, little differences in plasma
Aβ40 levels were observed between SGSM-36 and vehicle treated
groups. However, SGSM-36 decreased plasma Aβ42 levels by 46.2%
compared to vehicle (p b 0.01) (Fig. 1D), which resulted in a substantial
reduction of the Aβ42: Aβ40 ratio in plasma (41.1% decrease) as com-
pared to control (p b 0.05) (Fig. 1E). Analysis of brain Aβ (42:40) ratios,
which drives the β-amyloid burden, found that acute treatment with
SGSM-36 decreased Aβ (42:40) ratios in both brain soluble andnd preferentially decreased Aβ42 levels and changed the Aβ (42:40) ratios in Tg2576mice.
led to generation of aminothiazole-derived compound SGSM-36 (A). SGSM-36was applied
ale Tg2576micewere treatedwith vehicle (80% PEG-400 v/v; n= 8) or 25mg/kg SGSM-
TBS-insoluble solutions. Brain samples and plasma were then applied to MesoScale Aβ
arent compound NGP-555 and SGSM-36. B. SGSM-36 did not significantly decrease brain
tly decreased brain TBS-insoluble Aβ42 levels versus vehicle (p b 0.05). D. SGSM-36
ased Aβ (42:40) ratios in brain TBS-insoluble portion and plasma. Mean ± S.E.; ANOVA;
97F. Raven et al. / EBioMedicine 24 (2017) 93–101insoluble samples by 34.0% and 26.8%, respectively, which however
were below the statistical significance level (p values N 0.05; Fig. 1E).
Collectively, our data show that SGSM-36 preferentially decreases
brain and plasma Aβ42 levels in Tg2576 mice. These results are consis-
tent with the effects of the parent 2-aminothiazole GSM in these mice
(Kounnas et al., 2010).Fig. 2. SGSM-36 did not significantly affect APP processing via α-, or β-secretase in ADmouse b
Western blotting analysis (via 6E10 and sAPPβ antibody, respectively) using mouse brain TBS-s
normalization of proteins of interest. Bottom row is thedensitometric quantification ofWB. n=
CTFα or β) were analyzed in mouse brain MTBS samples by WB using the G12A antibody. B
quantification. n = 8 (vehicle) and n = 7 (SGSM-36). *, nonspecific band. C–D. SGSM-36 pre
levels of all Aβ species (D). APPIndiana-expressing 7PA2 cells were treated with different dose
the levels of Aβ (40,38,42). E. SGSM-36 did not change the levels of APP-CTFs, unlike sem
semagacestat or SGSM-36 for up to 24 h. Lysates were applied to WB to detect full length APP
36 preferentially decreased the levels of Aβ42 over Aβ40, while increased Aβ38 levels in 3D–
mutations and PSEN1 δE9 mutation were 3D–differentially for 5 weeks and then treated wit
calculate Aβ levels. n = 5; Mean ± S.E.; ANOVA; ***p b 0.001.3.2. SGSM-36 Does Not Affect α or β-secretase Processing of APP in Tg2576
Mice
To expand upon prior research and gain insights with respect to the
effects of SGSM-36 on APP processing, Western blot analysis of mouse
brains treated with SGSM-36 or vehicle was performed. Measurementrains and cells with FAD mutations. A. sAPPα and sAPPβ proteins were detected through
oluble samples. Additionally, a house-keeping protein, β-actin was used as the control for
8 (vehicle) and n=7 (SGSM-36). B. APP full length and proteolytic fragments (APP_FL and
ottom row is the densitometric quantification of WB. Bottom row is the densitometric
ferentially decreased Aβ42 levels (C), unlike semagacestat (a GSI) which decreased the
s of semagacestat or SGSM-36 for up to 24 h. Medium was applied to Aβ-MSD to detect
agacestat which increased APP-CTFs. 7PA2 cells were treated with different doses of
and APP-CTFs via the G12A antibody. β-Actin was used as the loading control. F. SGSM-
differentiated FAD HReN cells. The FAD HReN cells expressing APP Swedish and London
h 400 nM SGSM-36 or DMSO for another 2 weeks. Medium were applied to Aβ-MSD to
98 F. Raven et al. / EBioMedicine 24 (2017) 93–101of sAPPα (via 6E10 antibody) and sAPPβ (via sAPPβ antibody) in the
TBS-soluble fraction revealed that there was no statistically significant
impact upon α or β-secretase processing of APP when comparing vehi-
cle and SGSM-36 treatment (p N 0.05) (Fig. 2A). Particularly, we ob-
served that SGSM-36 decreased the levels of sAPPβ by 10.8%
compared to control (p N 0.05).
As a means to interrogate target specificity, membrane protein-con-
taining, or MTBS portions, were utilized to detect full length APP (APP-
FL) and APP-CTFs via G12A, a previously reported antibody targeting
APP-CTFs (Griciuc et al., 2013; Wang et al., 2015). As anticipated,
SGSM-36 did not affect the levels of full length APP (Fig. 2B). Addition-
ally, SGSM-36 did not alter the levels of APP-CTFβ or APP-CTFα, the
cleavage products of BACE-1 and α-secretase, respectively (Fig. 2B).
Specifically, SGSM-36 decreased the levels of APP-CTFα and APP-CTFβ
by 26.08% and 20.48%, respectively, compared to control (p values N
0.05). As a result of the mode of action and target selectivity exhibited
by SGSM-36, compound treatment did not increase the levels of APP
proteolytic processing products via α or β-secretase as observed with
conventional GSIs.
3.3. SGSM-36 Preferentially Decreases Aβ42 Levels in Cells Expressing FAD
Mutations, but Not Semagacestat
In order to further explore the potential of this compound, Aβ levels
weremeasured in cellswith an alternative FADmutation inAPP following
treatment with SGSM-36, semagacestat, or vehicle. A CHO cell line stably
expressing human APP751 bearing the V717F Indiana mutation (also
known as 7PA2 cells) (Welzel et al., 2014), which expresses N10-fold
higher levels of Aβ40 and Aβ42 compared to CHO-APP751 cells (Zhang
et al., 2010c), was treated with SGSM-36 at concentrations of 0, 3, 30,
300, 3000, and 30,000 nM for 24 h. Collection of the medium showed
that SGSM-36 decreased both Aβ40 andAβ42 levels,while simultaneous-
ly increasingAβ38 levels. Consistentwith prior report using SH-SY5Y cells
stably overexpressing human APP751 (Wagner et al., 2014), the IC50
values for Aβ40 andAβ42 inmediumwere 214.50 nMand106.10 nM, re-
spectively, and the EC50 value for Aβ38 levels in medium was 90.94 nM
(Fig. 2C). Conversely,7PA2 cells treated with semagacestat (0, 4.8, 24,
120, 600, and 3000 nM) for 24 h showed decreases in all Aβ speciesmea-
sured from medium with IC50 values of 21.69 nM, 38.25 nM, and
46.66 nM for Aβ38, Aβ40, and Aβ42 respectively (Fig. 2D).
In addition, the impact of treatment with SGSM-36 or semagacestat
uponγ-secretase processing of APPwas determined byWBanalysis uti-
lizing the G12A antibody to assess full length APP and APP-CTFs levels.
Incubation with semagacestat up-regulated the levels of APP-CTFs in
addition to a less pronounced increase in full length APP, while SGSM-
36 did not affect the APP-CTFs or full length APP levels in 7PA2 cells
(Fig. 2E). Furthermore, the 3D human neural cell culture expressing
APP Swedish and London mutations and PSEN1 δE9 mutation, also
known as HReN-mGAP cells were utilized to validate the roles of
SGSM-36 on Aβ levels. These cells were 3D-differentially for 5 weeks
and then treated with 400 nM SGSM-36 or DMSO for another
2 weeks. SGSM-36 led to a significant decrease in Aβ40 and Aβ42
level by 61.8% and 84.9%, respectively, as well as an increase in Aβ38
by 182.5%, compared to control (n = 5; ANOVA; p values b 0.001)
(Fig. 2F). Notably, SGSM-36 significantly decreased Aβ (42:40) ratios
by 60.4% compared to control (p b 0.001) (Fig. 2F). The raw values of
Aβ levels were also represented (Supplementary Fig. 2). Collectively,
SGSM-36 preferentially decreased Aβ42 levels in AD transgenic mice
and various model cells with FAD mutations in APP without affecting
α- or β-secretase processing of APP.
3.4. SGSM-36 Does Not Affect Notch Processing in Tg2576 Mice and Cells
Expressing FAD Mutations
Next, the effect of treatment with SGSMs versus GSIs on Notch pro-
cessing, an essential event during development, was compared (Kopanet al., 1994). Mouse brain MTBS samples were examined by WB using
the monoclonal Notch1 antibody. Consistent with the results of other
SGSMs using cell-based models, treatment with SGSM-36 did not influ-
ence the levels of cleaved Notch1 protein (Notch1-CTF), as compared to
vehicle (p N 0.05) (Fig. 3A). In addition, the effects of SGSM-36 on Notch
processing were further validated using APPIndiana-expressing 7PA2
cells, as compared to semagacestat. 7PA2 cells were transfected with
the NδED construct and then treated with different doses SGSM-36
(up to 20,000 nM) or semagacestat (up to 2000 nM) for 24 h. Cell lysates
were applied to WB and Myc antibody was utilized to assess the NδED
and NICD tagged with Myc on their C-termini. SGSM-36 treatment did
not change the NICD levels at any concentration studied, while
semagacestat decreased NICD levels even at low concentrations (Fig.
3B). Collectively, these experiments demonstrate that this class of
SGSMs reliably utilizes a mechanism of action which modulates γ-
secretase resulting in preferentially decreasingAβ42 levelswhile not af-
fecting the enzyme's processing of Notch.
3.5. SGSM-36 Modulates PS1 Conformational Change
Next, we investigated the potential roles of SGSM-36 on PS1 confor-
mational changes using a fluorescence lifetime imaging microcopy
(FLIM) assay, which have been well-established to reliably monitor
changes in Aβ (42:40) ratios (Uemura et al., 2010, 2009). Specifically,
the FRET efficiencies between the fluorophores labelling PS1 N-termi-
nus and loop domain in CHO-APP751 cells transfected with the GFP-
PS1-RFP FRET reporter probe (Uemura et al., 2009) (Fig. 4A), as well
as mouse primary neurons immunostained with fluorescently labeled
antibodies against endogenous PS1 N- and C-termini were assessed
(Fig. 4B). The cells were pre-treated for 16 h with SGSM-36 or vehicle
control and the FRET efficiency was subsequently reported for outlined
whole-cell and cell periphery of CHO-APP751 cells transfected with
GFP-PS1-RFP FRET reporter (Fig. 4A), and for cell bodies and processes
of mouse primary neurons expressing PS1 at endogenous levels (Fig.
4A). The average FRET efficiency between the fluorophores labelling
the PS1 subdomains after SGSM-36 treatment was reduced in both
CHO-APP751 and primary neurons, as compared to the vehicle controls
(Fig. 4A–B). The decrease was most profound at the periphery of the
CHO cells and in the neuronal processes, which represent the mem-
brane-enriched structures. The consistent reduction of the FRET effi-
ciency in both SGSM-36 treated cell types indicates the decrease in
the proximity between the PS1 NT and CT loop domains, reflective of
the predominantly “open” non-pathogenic PS1 subdomain arrange-
ment. Collectively, the FLIM-based PS1 conformational analyses provide
furthermechanistic insight into how SGSMs decrease Aβ (42:40) ratios.
4. Discussion
Although AD is a genetically complex disease, 225 known familial
AD (FAD) mutations in PSEN1 and PSEN2 afford direct evidence for the
importance of PS1 and γ-secretasewith respect to the disorder. In addi-
tion, most of the 51 FAD mutations in APP are also characterized by al-
tered biological activity of γ-secretase directly affecting the type of Aβ
species produced. Biochemical studies of these mutations show a com-
mon endpoint which is primarily characterized by increases in the
levels of Aβ42 and the Aβ (42:40) ratios, driving the aggregation of
Aβ into neurotoxic oligomeric assemblies (Bertram and Tanzi, 2008;
Tanzi and Bertram, 2005). Therefore, elucidating the physiological and
pathophysiological roles of γ-secretase, and its cleavage products, (e.g.
Aβ) are key to evaluating the therapeutic potential of this target for
the treatment of AD.
The strong implication based on the genetics of AD that the constitu-
tion of the Aβ fragments is a central cause of AD led to γ-secretase
emerging as a prime therapeutic target. Initially, GSI's garnered intense
interest based on their ability to reduce the levels of all Aβ species
through a broad-based inhibitory mechanism. However, inhibition of
Fig. 3. SGSM-36 did not change proteolytic processing of Notch, while semagacestat inhibited Notch processing. A. SGSM-36 did not change Notch processing in Tg2576 mice brains
compared to vehicle. SGSM-36 or vehicle-treated mouse brain MTBS proteins were applied to WB and detected by the Notch antibody. Bottom row is the densitometric quantification.
n = 8 (vehicle) and n = 7 (SGSM-36). B. SGSM-36 did not inhibit Notch processing, while semagacestat down-regulated Notch processing in APPIndiana-expressing 7PA2 cells. 7PA2
cells were transfected with the NδED construct and then treated with different doses SGSM-36 or semagacestat for additional 24 h. Cells were harvested 48 h post transfection and
applied to WB. Myc antibody was utilized to assess the NδED and NICD tagged with Myc on their C-termini. SGSM-36 did not inhibit Notch processing at all concentrations tested,
while semagacestat inhibited Notch processing.
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ment arrested the proteolytic processing of alternative γ-secretase sub-
strates including Notch leading to significant adverse events.
Additionally, inhibiting the processing of APP resulted in the accumula-
tion of upstream CTFs, particularly APP-CTFβ, which is responsible for
initiating neurodegenerative process and cognitive decline (Lauritzen
et al., 2012). The failure of GSIs as a therapy for AD fueled intense scru-
tiny of γ-secretase as a target and led to various studies in the genetics,
biochemistry and pharmacology to determine the biological roles and
numerous substrates of the enzyme.
Despite the stigma attached to targeting γ-secretase engendered
by GSI's, an alternative class of small molecules, known as GSMs, has
been developed, which bind to an allosteric site within the enzyme
(Uemura et al., 2010, 2009) and modulate the Aβ isoforms pro-
duced. Specifically, GSM treatment attenuates the production of
the longer, more fibrillogenic Aβ42 peptide in favor of shorter and
more soluble species (i.e. Aβ37 and Aβ38). Since GSMs do not inter-
fere with γ-secretase function, these compounds are likely avoiding
the adverse events of GSI's. The clear mechanistic differentiation of
GSIs and GSMs is paramount to the development of GSMs for the
treatment and prevention of AD. To this end, a thorough investiga-
tion of the molecular endo-phenotypes using both cell- and ani-
mal-based models of AD, comparing a conventional GSI and a
SGSM currently under development has been described in the cur-
rent study.
During the course of the development of aminothiazole-derived
small molecule GSMs, SGSM-36 (Fig. 1A) was discovered and exhibitedFig. 4. SGSM-36modulates conformation of PS1. SGSM-36 led to reductions in the FRET efficien
mouse neurons (B). A. CHO-APP751 cells transfectedwithGFP-PS1-RFPwere treatedwith vehic
the GFP and RFP proximity on PS1 NT and transmembrane 6–7 loop domains, respectively. Re
vehicle. Mean ± S.E.; n = 30–40 from 3 independent experiments. B. Primary mouse neuron
based FLIM assay to monitor conformational changes in endogenous PS1. Reduction in the F
Mean ± S.E.; n = 35–81 neurons from 3 independent experiments. Two-tailed unpaired Studgood activity for suppressing the production of Aβ42 (Aβ42 IC50 =
63 nM) (Rynearson et al., 2016; Wagner et al., 2014). In addition,
SGSM-36 exhibited improved physicochemical properties with respect
to the parent compound including good aqueous solubility, as well as
acceptable in vivo pharmacokinetic behavior in mice (Wagner et al.,
2014). In order to build upon prior studies, a thorough in vivo efficacy
analysis of SGSM-36 using Tg2576 mice showed that treatment at
25 mg per kg for 3 consecutive days was effective at reducing brain
(Fig. 1B–C) and plasma (Fig. 1D) Aβ42 levels and Aβ (42:40) ratios in
both brain and plasma (Fig. 1E). In comparison to the parent compound
NGP-555 (or compound-4) (Kounnas et al., 2010), a nearly 2-fold
superior decrease in brain Aβ42 levels was achieved following treat-
ment with SGSM-36, although there is a greater than six-fold disparity
between the in vitro Aβ42 IC50 values of the parent compound and
SGSM-36 (Kounnas et al., 2010; Wagner et al., 2014). Furthermore,
the parent compound NGP-555 was 2-fold superior to SGSM-36 for
reducing plasma Aβ42 levels, suggesting that the highly lipophilic na-
ture of this compound is resulting in sequestration of the drug in the pe-
riphery which likely associated with high plasma protein binding
thereby limiting the effect in the brain. Additionally, the efficacy data
belies the brain to plasma ratio of the parent compound and SGSM-36
(brain:plasma = 0.93 and 0.54, respectively), demonstrating that the
ratio can be a valuable tool to assess whether a compound can cross
the blood-brain barrier but is unlikely to accurately capture the in vivo
activity of a given compound. Based on the efficacy data, SGSM-36
exhibits good therapeutic potential, since the overall goal of treatment
is to reduce Aβ42 in the brain. Furthermore, SGSM-36 clearlycy, indicative of the “open” PS1 conformation, in both CHO-APP751 cells (A) and primary
le or 500nMSGSM-36 for 16 h. The PS1 conformationwas analyzedby FLIMviamonitoring
duction in the FRET efficiency was recorded upon SGSM-36 treatment and compared to
s were treated with vehicle or 200 nM SGSM-36, for 16 h and then applied to antibody-
RET efficiency was recorded in neurons upon SGSM-36 treatment compared to vehicle.
ent's t-test, *p b 0.05; ****p b 0.0001.
100 F. Raven et al. / EBioMedicine 24 (2017) 93–101demonstrates that strategies which account for physicochemical prop-
erties can be applied to the identification analogs with improved
potential.
To address target specificity in vivo, samples from Tg2576 mouse
brains and cell lysates transfectedwithNotch constructswere subjected
to western blot analysis. Distinct from GSIs, SGSM-36 did not affect the
levels of cleaved Notch1 protein in mouse brains (Fig. 3A) and NICD
levels in cells (Fig. 3A) indicating a unique mechanism of action that
does not interferewith γ-secretase, thereby precluding inhibition relat-
ed side-effects. Moreover, detection of upstream cleavage products,
sAPPα and sAPPβ, shows that SGSM-36 does not impact enzymatic pro-
cessing of APP by BACE-1 or α-secretase, indicating that the observed
shift in the Aβ profile results from modulation of the γ-secretase en-
zyme (Fig. 2A and B).
A comparison of themode of action of SGSM-36 and semagacestat, a
GSI, was also conducted using a CHO cell line stably expressing human
APP751 bearing the V717F Indiana mutation. Although the sequence
of APP is distinct from the aforementioned in vivo study, SGSM-36 treat-
ment resulted in dose-dependent decreases in Aβ42 and Aβ40, as well
as a dose-dependent increase Aβ38, whereas reduction of all three Aβ
analyzed was associated with semagacestat treatment (Fig. 2C and D).
Consistent with discrete mechanisms of action, SGSM-36 modulates
the constitution of the Aβ peptide profile, while semagacestat inhibits
enzyme function. Analysis of APP-CTFs further supports the observed
activities. SGSM-36 did not influence the levels APP-CTFs; however,
the GSI, semagacestat showed dose-dependent accumulation of the γ-
secretase substrate (Fig. 2E). The effects of SGSM-36 on Aβ levels in
the CHO cell linewere validated in our human 3D–differentiated neural
cell culture expressing FAD mutations containing APP K670N/M671L
(Swedish) and V717I (London) mutations and PSEN1 δE9 mutation
(Fig. 2F). The presented characterization of the mechanisms of these
pharmacological agents which target γ-secretase serves to distinguish
GSMs from GSIs with respect to their impact upon the biological roles
of γ-secretase. By avoiding inhibition of the γ-secretase enzyme,
SGSM-36 will avoid instigating the side effects of GSIs while still effica-
ciously impacting the primary biomarker associated with AD, Aβ42.
These studies encourage further evaluation of SGSM-36 toward the de-
velopment of an amyloid directed therapy. The results of this study also
warrant investigation of the roles of SGSM-36 on other γ-secretase re-
lated activity and proteins, e.g. AICD protein.
GSIswere shown to effectively decrease Aβ levels at doses close to or
higher than their IC50 values in cell culture models. Surprisingly, they
also slightly increase Aβ levels at low doses, (significantly below the
IC50) also known as “Aβ rise”, due to various mechanisms including in-
hibition of cellular γ-secretase activity (Barnwell et al., 2014; Burton et
al., 2008; Citron et al., 1996; Lanz et al., 2006;Mitani et al., 2012). Partic-
ularly, a potent peptidomimetic GSI, semagacestat, increases Aβ42
levels at low doses in H4 cells stably over-expressing an FAD-linked
Swedish double mutation and also increases Aβ42 levels in CSF and
plasma of treated guinea pigs. These preclinical outcomes recapitulate
the biomarker results of semagacestat's clinical trials for AD (Fleisher
et al., 2008).
Previous studies have shown that PS1 exists in a dynamic equilibri-
um of different conformational states, characterized by varied proxim-
ities between the PS1 NT and CT large cytosolic loop domain (Kuzuya
et al., 2016; Maesako et al., 2017; Uemura et al., 2010). Importantly,
PS1 subdomain arrangement strongly correlates with the changes in
Aβ (42:40) ratios (Kuzuya et al., 2016; Maesako et al., 2017; Uemura
et al., 2010; Zoltowska et al., 2017). For example, fenofibrate, an
antilipidemic agent that potently increases the Aβ (42:40) ratios
(Kukar et al., 2005) leads to shortening of the donor fluorophore life-
time (τ1) and increased FRET efficiency, which indicates a closer prox-
imity of PS1 subdomains, or ‘closing’ of PS1 conformation (Uemura et
al., 2010). Alternatively, ibuprofen, a small molecule that belongs to
the group of nonsteroidal anti-inflammatory drugs (NSAIDs) known
to decrease the Aβ (42:40) ratios results in “opening” of PS1conformation (Uemura et al., 2010). Taken together, a pharmacological
agent that elicits an “opening” of PS1 conformation should preferential-
ly decrease relative levels of the longer, Aβ42 species andmay have po-
tential as a treatment for AD. Consistent with the in vitro and in vivo
results showing attenuation of Aβ42, the antibody-based FLIM PS1 con-
formation assay demonstrate that SGSM-36 induces a conformational
shift within the endogenous PS1 molecule toward the “open”, non-
pathogenic state (Fig. 4A and B). The FRET data points toward a poten-
tial molecular mechanism in which SGSM-36 reduces Aβ (42:40) ratios
by instigating a shift in the structure of the enzyme resulting in en-
hanced proteolytic processing of the substrate.
In summary, acute treatmentwith SGSM-36 led to significant reduc-
tion in plasma and brain Aβ42 levels in Tg2576mice. Thorough scrutiny
of the in vivo and in vitromechanismof action studies demonstrate that
SGSM-36 suppresses the formation of Aβ42 through the modulation of
the γ-secretase enzyme in a fashion distinct from previously developed
GSIs. Collectively, these results indicate that using SGSMs are a superior
therapeutic approach for addressing amyloid when compared to con-
ventional GSIs. The good in vivo efficacy observed for SGSM-36 war-
rants further study toward the development of an effective therapy for
the treatment and prevention of AD.
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